MedCity News
Telehealth aside, providers look to invest IT dollars in cloud services, data analytics
Though telehealth will continue to account for a large portion of healthcare IT budgets in 2021, there are other technology-based services driving provider interest. These range from cloud deployment to vaccine scheduling solutions as providers navigate the new landscape created by the Covid-19 pandemic.
Shares0
Provider IT spending is expected to grow from $113 billion last year to $131 billion in 2022, according to data from Gartner. This huge jump will of course include spending on virtual care services but there is more on providers’ minds.
With the shift to digital showing no signs of slowing down, providers are also looking at cloud services, vaccine scheduling solutions and data analytics to boost their clinical offerings and improve patient experience.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
A journey from despair to hope: One man finds healing with hernia care bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
MedCity News
Achilles Therapeutics’ IPO nabs $175M to bring cell therapies to solid tumors
The Achilles Therapeutics IPO comes as several other biotechs make progress developing a type of cancer immunotherapy called a tumor-infiltrating lymphocyte. Clinical-stage Achilles contends its approach could best them all.
Shares0
FDA approval of cell therapies made from a patient’s own immune cells provided another treatment option for the most serious cases of blood cancer. But this type of treatment, called CAR-T therapy, is cumbersome to manufacture and still hasn’t proven effective in solid tumors.
A different type of cell therapy called tumor infiltrating lymphocytes (TIL) could offer yet another alternative, plus the potential to address solid tumors. Several biotechs have TILs in clinical development. Achilles Therapeutics aims to best them all.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.